Last reviewed 2026-06-10 · How we verify

BRCA1/2-mutated and HRD-positive advanced solid tumors — Treatment Landscape & Competitive Intelligence

BRCA1/2-mutated and HRD-positive advanced solid tumors (disease) competitive landscape: 0 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating BRCA1/2-mutated and HRD-positive advanced solid tumors, deduplicated by molecule. See the full disease page for line-of-therapy detail.

No marketed treatments tracked for this disease yet.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Duke University · 1 drug in BRCA1/2-mutated and HRD-positive advanced solid tumors

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in BRCA1/2-mutated and HRD-positive advanced solid tumors:

• BRCA1/2-mutated and HRD-positive advanced solid tumors treatment updates — RSS
• BRCA1/2-mutated and HRD-positive advanced solid tumors treatment updates — Atom
• BRCA1/2-mutated and HRD-positive advanced solid tumors treatment updates — JSON

Cite this brief

Drug Landscape (2026). BRCA1/2-mutated and HRD-positive advanced solid tumors — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/brca1-2-mutated-and-hrd-positive-advanced-solid-tumors. Accessed 2026-06-10.

Related

• BRCA1/2-mutated and HRD-positive advanced solid tumors full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing